In summary, our results provide a novel insight into how melanoma cells engage in bidirectional interactions with the immune system, highlight the importance of MITF and melanoma phenotype in shaping the anti-melanoma immune response, and suggest that targeting ADAM10 may represent a complementary therapeutic approach to current T-cell-based immunotherapies. This evidence concerns the gene ADAM10 and melanoma.